Solana Company Q1 FY2024 Earnings Call

· Earnings call transcript and AI-powered summary

Helius Medical Technologies Q1 2024 Earnings Summary

  • Revenue: $135,000 for Q1 2024, up 22% from $111,000 in Q1 2023. Increase attributed to higher product sales in the U.S. and Canada.
  • Cost of Revenue: Flat year-over-year at $123,000 in Q1 2024 vs. $122,000 in Q1 2023.
  • Operating Loss: Reduced to $3.4 million in Q1 2024 from $3.8 million in Q1 2023.
  • Net Loss: $2.5 million in Q1 2024, unchanged from Q1 2023, but loss per share improved to $3.08 from $4.42 due to share count changes.
  • Cash Position: $3.6 million as of March 30, 2024, with no debt. A $6.4 million equity financing closed in May 2024 extends cash runway into 2025.
  • Cash Burn: Decreased to $3.0 million in Q1 2024 from $3.2 million in Q1 2023.

Operational and Strategic Highlights

  • Reimbursement Progress: CMS established unique HCPCS codes for PoNS controller and mouthpiece, effective April 1. Awaiting final payment determinations expected by October 1, which could accelerate third-party reimbursement adoption.
  • Pricing: PoNS list price in North America is $25,700—$17,800 for the controller and $7,900 for the mouthpiece.

Continue Reading

Unlock the full AI-powered summary with key highlights, financial performance, and analyst Q&A.

Upgrade to Professional
Operator: Good day and thank you for standing by. Welcome to the Helius Medical Technologies First Quarter 2024 Earnings Conference Call. [Operator Instructions] Please be advised today's conference is being recorded. I would now like to hand the conference to your speaker today, Michelle Bilski with In-Site Communications. Please go ahead. Michelle Gable Bilski: Thank you, Kevin. Welcome to the First Quarter 2024 Earnings Conference Call for Helius Medical Technologies. This is Michelle Bilski an In-Site Communications Investor Relations for Helius. With me on today's call are Dane Andreeff, Helius Medical's President and Chief Executive Officer; and Jeff Mathiesen, Chief Financial Officer. [Operator Instructions] Please note that this call is being recorded, and access to the webcast can be obtained through the Investors section of the Helius website at, www.heliusmedical.com. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management. These forward-looking statements, including statements regarding potential reimbursement pricing involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including those identified in the Risk Factors section of our most recent annual report on Form 10-K. Such factors may be updated from time to time in our other filings with the SEC, whi

Continue Reading

Unlock the full earnings call transcript with speaker labels and formatted dialogue.

Upgrade to Professional